Diabetology & Metabolic Syndrome

Table 2 Effect of lactoferrin on the serum levels of SOD, IL-1β, -6, -18 and lipocalin in type 2 diabetic patients

From: Antidiabetic efficacy of lactoferrin in type 2 diabetic pediatrics; controlling impact on PPAR-γ, SIRT-1, and TLR4 downstream signaling pathway

Variables	Diabetic patients (N = 30)		Controls (N = 30)
Variables	Before lactoferrin	After lactoferrin	Controls (N = 30)
SOD (U/mL)	143.6 ± 9.344^a	175.9 ± 10.3^b	222.5 ± 14.9
Interleukin-1β (pg/mL)	13.8 ± 1.8^a	10.45 ± 1.37^b	3.4 ± 0.8
Interleukin-6 (pg/mL)	16.78 ± 2^a	11.5 ± 1.89^b	4.9 ± 1.0
Interleukin-18 (pg/mL)	46.9 ± 6.4^a	30.67 ± 4.15^b	15.5 ± 2.87
Lipocalin 2 (pg/mL)	102.2 ± 11.7^a	66.36 ± 13.2^b	25.6 ± 3.9

Values are means ± SDM
SOD superoxide dismutase, IL interleukin
^aSignificant difference from normal group, at P ≤ 0.05
^bSignificant difference from diabetic patients before therapy, at P ≤ 0.05

Back to article page

ISSN: 1758-5996

Contact us

Submission enquiries: journalsubmissions@springernature.com